SAV001-H is the first candidate preventive HIV vaccine using a killed or "dead" version of the HIV-1 virus (inactivated vaccine).
The vaccine was developed by Dr. Chil-Yong Kang and his research team at Western University’s Schulich School of Medicine & Dentistry in Canada.
The results of the Phase I clinical trial, completed in August 2013, showed no serious adverse effects in 33 participants.